Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jun 1;4(6):798-804.
doi: 10.1001/jamaoncol.2018.0137.

Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer

Bette J Caan  1 , Elizabeth M Cespedes Feliciano  1 , Carla M Prado  2 , Stacey Alexeeff  1 , Candyce H Kroenke  1 , Patrick Bradshaw  1 , Charles P Quesenberry  1 , Erin K Weltzien  1 , Adrienne L Castillo  1 , Taiwo A Olobatuyi  2 , Wendy Y Chen  3
Affiliations
Observational Study

Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer

Bette J Caan et al. JAMA Oncol. .

Abstract

Importance: Sarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown.

Objective: To evaluate associations of all 3 body composition measures, derived from clinically acquired CT at diagnosis, with overall mortality in nonmetastatic breast cancer.

Design, setting, and participants: This observational study included 3241 women from Kaiser Permanente of Northern California and Dana Farber Cancer Institute diagnosed from January 2000 to December 2013 with stages II or III breast cancer. We calculated hazard ratios (HRs) to evaluate the associations of all-cause mortality with sarcopenia, low muscle radiodensity, and total adipose tissue (TAT). Models were adjusted for sociodemographics, tumor characteristics, treatment, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), and other body composition measures. We also evaluated the cross-classification of categories of sarcopenia (yes/no) and tertiles of TAT, with outcomes.

Main outcomes and measures: Overall survival time and all-cause mortality.

Results: Median (range) age of 3241 women included in this study was 54 (18-80) years, and median follow-up was 6.0 years; 1086 patients (34%) presented with sarcopenia, and 1199 patients (37%) had low muscle radiodensity. Among patients with nonmetastatic breast cancer, those with sarcopenia showed higher overall mortality (HR, 1.41; 95% CI, 1.18-1.69) compared with those without sarcopenia. Patients in the highest tertile of TAT also showed higher overall mortality (HR, 1.35; 95% CI, 1.08-1.69) compared with those in the lowest tertile. Low radiodensity was not associated with survival. In analyses of sarcopenia and TAT, highest mortality was seen in patients with sarcopenia and high TAT (HR, 1.89; 95% CI, 1.30-2.73); BMI alone was not significantly related to overall mortality and did not appropriately identify patients at risk of death owing to their body composition.

Conclusions and relevance: Sarcopenia is underrecognized in nonmetastatic breast cancer and occurs in over one-third of newly diagnosed patients. Measures of both sarcopenia and adiposity from clinically acquired CT scans in nonmetastatic patients provide significant prognostic information that outperform BMI and will help to guide interventions to optimize survival outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Patient Survival
Kaplan-Meier curves show survival rates for patients with (A) sarcopenia, with (B) low muscle radiodensity, and (C) in high, medium, or low tertiles of total adiposity. CT indicates computed tomography.
See this image and copyright information in PMC

Comment in

References

    1. Ligibel JA, Wollins D. American Society of Clinical Oncology obesity initiative: rationale, progress, and future directions. J Clin Oncol. 2016;34(35):4256-4260. - PubMed
    1. Kwan ML, Chen WY, Kroenke CH, et al. . Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012;132(2):729-739. - PMC - PubMed
    1. Chan DS, Vieira AR, Aune D, et al. . Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901-1914. - PMC - PubMed
    1. Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between body mass index (BMI) and cancer survival in a pooled analysis of 22 clinical trials. Cancer Epidemiol Biomarkers Prev. 2017;26(1):21-29. - PMC - PubMed
    1. Del Fabbro E, Parsons H, Warneke CL, et al. . The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240-1245. - PMC - PubMed

Publication types

MeSH terms